On May 2, 2013, HEALTHSOUTH Corp.'s Board appointed Ms. Katz to serve on its Audit Committee and Nominating/Corporate Governance Committee and Ms. Herman to serve on its Compensation Committee and Compliance/Quality of Care Committee.

HEALTHSOUTH Corp. Presents at UBS Global Healthcare Conference, May-22-2013 09:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Douglas E. Coltharp, Chief Financial Officer and Executive Vice President, Jay F. Grinney, Chief Executive Officer, President and Director, Mary Ann Arico, Senior Vice President of Investor Relations and Corporate Communications.

HEALTHSOUTH Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the first quarter of 2013, consolidated net operating revenues were $572.6 million, compared to $538.6 million for the first quarter of 2012, or an increase of 6.3%. This increase was attributable to a 4.1% increase in patient discharges and a 3.1% increase in net patient revenue per discharge. Net patient revenue per discharge increased primarily due to pricing adjustments from Medicare and managed care payors, higher patient acuity, and a higher percentage of Medicare patients. Income from continuing operations attributable to the company per share was $0.48 per share compared to $0.40 per share for the same period of 2012. Earnings per share for the first quarter of 2013 reflected strong operating results and higher depreciation and amortization related to increased capital investment in 2012. Cash flows provided by operating activities were $121.4 million, compared to $81.0 million for the same period of 2012. This increase was primarily due to increased net operating revenues and continued disciplined expense management. Adjusted EBITDA was $139.3 million compared to $127.0 million for the three months ended March 31, 2012, or an increase of 9.7%. This improvement was due primarily to continued revenue growth and disciplined expense management offset by higher expense associated with the ongoing implementation of the company's electronic clinical information system and higher non-controlling interest expense. Adjusted free cash flow was $85.7 million compared to $45.2 million for the same period of 2012. Increases to adjusted free cash flow resulted from continued Adjusted EBITDA growth and a decrease in working capital. Income from continuing operations before income tax expense was $99.8 million, compared to $86.3 million for the last year. Income from continuing operations was $66.3 million, compared to $57.2 million for the last year. Net income attributable to common shareholders was $45.6 million or $0.48 per diluted share, compared to $37.3 million or $0.39 per diluted share for the last year. Purchase of property and equipment was $30.1 million, compared to $27.2 million for the last year. The company provided 2013 guidance which consisted of adjusted EBITDA in the range of $506 million to $516 million and income from continuing operations attributable to the company per share in the range of $1.50 to $1.56 per share. As a result of the common stock tender offer completed by the company in the first quarter of 2013, the company is updating its earnings per share guidance range to $1.61 to $1.68 solely to reflect a lower share count and higher interest expense resulting from the repurchase of approximately 9.1 million common shares in March 2013. Based on its results for the first quarter of 2013, the company expects its 2013 full-year adjusted EBITDA and earnings per share to be at the high end of, or higher than, these guidance ranges. Assumption for full year 2013 interest expense has been increased by $2 million due to the funding of the common stock tender completed in the first quarter. The company continue to expect working capital to increase in the range of $10 million to $20 million and maintenance CapEx of $80 million to $90 million for the full year of 2013. The company continued to invest a portion of free cash flow towards future growth with the on-going construction of three new hospitals and the purchase of the 58-bed Walton Rehabilitation Hospital in Augusta, Georgia.